multispecific

ADCs combine antibody targeting with potent drugs. Biointron outlines unique properties, advantages, and applications that make ADCs vital therapeutic tools.

AET Europe 2024 in London spotlighted antibody innovation. Biointron shares event takeaways on discovery, engineering, and development shaping the therapeutic pipeline.

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.